Mirum jumps as brelovitug Phase 3 enrollment milestone fuels optimism
Mirum Pharmaceuticals (MIRM) rose about 4% to $96.11 as investors reacted to progress in its Phase 3 hepatitis D program for brelovitug, including completed AZURE-1 enrollment and AZURE-4 screening. Recent analyst price-target increases also supported sentiment as the stock trades near record highs.
1. What’s moving the stock today
Mirum Pharmaceuticals shares moved higher in Wednesday trading (April 1, 2026), with the rally tied to improving confidence in the company’s late-stage hepatitis D (HDV) program. The company highlighted operational progress in its Phase 3 AZURE program for brelovitug, including completion of AZURE-1 enrollment and AZURE-4 screening, which investors often view as a de-risking step that brings data and regulatory planning into clearer view. (mirumpharma.com)
2. Why this milestone matters
Enrollment and screening completion can reduce execution uncertainty and refocus attention on upcoming readouts and the broader regulatory path. Mirum’s updated corporate materials outline expected timing for AZURE-1 and other program milestones, keeping the market’s focus on the cadence of data in 2026 and beyond. (ir.mirumpharma.com)
3. Secondary tailwinds: targets rising and momentum near highs
Separately, sell-side sentiment has been supportive, with a notable recent price-target increase to $125 alongside a Buy rating, reinforcing the view that Mirum’s HDV opportunity could meaningfully expand its rare liver disease franchise. With the stock already hovering near all-time highs, incremental positive developments can have an outsized impact on short-term price action. (sahmcapital.com)